Skip to content
Open access

ANTICONVULSANT EVALUATION 1,2,4 PYRIDINE-TRIAZOLE BASED SCHIFF BASE DERIVATIVES TARGETING THE GABA-A RECEPTOR: IN SILICO, IN VITRO AND IN VIVO STUDIES

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 4 references

Abstract

: Epilepsy affects over 50 million individuals worldwide and is characterized by recurrent seizures that are sometimes unresponsive to current therapies and induce negative effects, underscoring the urgent need for new anticonvulsant medications. This study examines the anticonvulsant effects of 1,2,4 pyridine triazole-based Schiff based on derivatives that target the GABA-A receptor, a critical inhibitory neurotransmitter site for seizure regulation. Fifteen new derivatives were produced and subjected to molecular docking using Auto Dock Tools 1.5.7 against the GABA-A receptor (PDB ID: 7DTD), indicating strong binding affinities for compounds D7, D3, D9 and D1, with docking scores of -0.9, -7.8, -7.1 and -6.4 kcal/mol, respectively. These compounds showed important contacts with the receptor active site residues. In vitro MTT testing on SHSY5Y neuroblastoma cells revealed more than 75% cell viability at 40 µg, suggesting excellent neuroprotection and low cytotoxicity. In vivo confirmation using the Pentylenetetrazol (PTZ) model in mice revealed that both D7 and D3 substantially reduced seizure duration (p < 0.05), similar to the standard drug benzodiazepine with no toxicity or mortality reported. The combined in silico, in vitro and in vivo findings indicate that 1,2,4 pyridine-triazole based Schiff base derivatives, notably D7 and D3, are promising candidates for developing effective and safer anticonvulsant drugs

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.